Matrix metalloproteinases-9 and -2 in secondary vasculitic neuropathies

[1]  P. Fuhr,et al.  Matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy , 1999, Neurology.

[2]  B. Sharrack,et al.  Randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculoneuropathy , 1999, Neurology.

[3]  S. Lorenzl,et al.  Matrix metalloproteinases contribute to the blood—brain barrier disruption during bacterial meningitis , 1998, Annals of neurology.

[4]  H. Hartung,et al.  Matrix metalloproteinases MMP‐9 and MMP‐7 are expressed in experimental autoimmune neuritis and the guillain‐barré syndrome , 1998, Annals of neurology.

[5]  R. Hughes,et al.  Matrix metalloproteinase expression during experimental autoimmune neuritis. , 1998, Brain : a journal of neurology.

[6]  Voon Wee Yong,et al.  Matrix metalloproteinases and diseases of the CNS , 1998, Trends in Neurosciences.

[7]  J. Cossins,et al.  Enhanced expression of MMP-7 and MMP-9 in demyelinating multiple sclerosis lesions , 1997, Acta Neuropathologica.

[8]  R. Hughes,et al.  A combined inhibitor of matrix metalloproteinase activity and tumour necrosis factor-alpha processing attenuates experimental autoimmune neuritis. , 1997, Brain : a journal of neurology.

[9]  J. Cossins,et al.  Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-α inhibitor , 1997, Journal of Neuroimmunology.

[10]  J. Newcombe,et al.  The Expression of Tissue‐type Plasminogen Activator, Matrix Metalloproteases and Endogenous Inhibitors in the Central Nervous System in Multiple Sclerosis: Comparison of Stages in Lesion Evolution , 1996, Journal of neuropathology and experimental neurology.

[11]  E. Waubant,et al.  Interferon beta‐1b inhibits gelatinase secretion and in vitro migration of human T cells: A possible mechanism for treatment efficacy in multiple sclerosis , 1996, Annals of neurology.

[12]  C. Ford,et al.  Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis , 1996, Neurology.

[13]  R. Sobel,et al.  Matrix Metalloproteinases in the Normal Human Central Nervous System, Microglial Nodules, and Multiple Sclerosis Lesions , 1996, Journal of neuropathology and experimental neurology.

[14]  S. Chandler,et al.  Matrix metalloproteinases degrade myelin basic protein , 1995, Neuroscience Letters.

[15]  S. Hauser,et al.  Stimulation of matrix metalloproteinase‐dependent migration of T cells by eicosanoids , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  E. Waubant,et al.  T cell gelatinases mediate basement membrane transmigration in vitro. , 1995, Journal of immunology.

[17]  L. Steinman,et al.  Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. , 1994, The Journal of clinical investigation.

[18]  A. M. Romanic,et al.  The induction of 72-kD gelatinase in T cells upon adhesion to endothelial cells is VCAM-1 dependent , 1994, The Journal of cell biology.

[19]  G. Opdenakker,et al.  Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. , 1993, Biochemical and biophysical research communications.

[20]  G. Opdenakker,et al.  Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders , 1992, Journal of Neuroimmunology.

[21]  Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP) , 1991, Neurology.

[22]  D. Conn.  Update on systemic necrotizing vasculitis. , 1989, Mayo Clinic proceedings.

[23]  G. Said,et al.  The peripheral neuropathy of necrotizing arteritis: A clinicopathological study , 1988, Annals of neurology.

[24]  H. Hartung,et al.  Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis. , 1998, Brain : a journal of neurology.

[25]  J. Degos,et al.  Treatment of Guillain-Barré syndrome with interferon-beta. , 1998, Lancet.

[26]  A. Ropper,et al.  Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. , 1998, Neurology.